
Objective

Evaluate the quality of evidence of included cohort studies or controlled trials.

Configure Risk of Bias

From administrative settings, select the ROB mode.



Choose Scope

Assess Risk of Bias the study level or the outcome level:

Administrator Settings: Opioid Use Disorder - Phase I

	Risk of Bias			
Choose a system:	Choose a scope:	Select Outcomes:		
System: SIGN 50, Version: 2011 🔹 🗸	Some systems allow you evaluate the risk of bias of entire studies or individual outcomes. ○ Entire Study ☑ Individual Outcomes	Data Element	Timepoint	Ro
		% Change employed	Outcome	C
		% abstinence	Outcome	
		% change insured	Outcome	
		% negative urine sample	Outcome	C
		Anxiety	Outcome	C
		COWS Scale	Outcome	
		Confusion	Outcome	ſ

Start Assessing Risk of Bias

?

Navigate to ROB Module

After selecting the system and scope, reviewers can begin assessing ROB. You may need to refresh. Once the page reloads, ROB will appear in the navigation menu.

Tagging	50/50	ed	
Configure Study Tags Study Inspector 4. VAS SCARE		e	
Extraction	50/50		
Study Inspector			
Risk of Bias Study Inspector	0/50		
Synthesis Manuscript Editor			
Export		.prenorphine(BUP)	Methadone (MTI
A		10.40	NA 11 1

Read study and select study type

Depending on the selected ROB system, you may need to select a Cohort Study or Controlled Study to begin assessment.



Nested Knowledge - https://wiki.nested-knowledge.com/

Assess study bias

Fill out the ROB questions as you read through the uploaded study.

Risk of Bias: Opioid Use Disorder - Phase I	0/50
Patient-centered Outcomes in Participants of a Buprenorphine	Avigation Back
Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.	Z Z Risk of Bias Study Type Study Type
Ξ Thomson 1 / 8 − 90% + 🗄 👌 🛓 🛱 🗄	Study Type Controlled Clinical Trial
Original Research	Internal Validity Itestudy addresses an appropriate and clearly focused question. Well covered (Yes) Comment The assignment of subjects to treatment groups is randomised.
OPEN	(Adequately addressed • v) Comment
Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study Walter Ling, MD, Vijay R. Nadipelli, MS, Caitlyn T. Solem, PhD, Naoko A. Ronquest, PhD, Yu-Chen Yeh, MS, Susan M. Learned, MD, Vishaal Mehra, MD, and Christian Heidbreder, PhD	An adequate concealment method is used. No Selection Well covered (Yes) Adequately addressed Poorly addressed Poorly addressed One Not addressed (no) Mot reported Not reported NA Comments (0)
Objective: Opioid use disorder (OUD) is associated with physical, social, psychological, and economic burden. This analysis assessed the effects of RBP-6000, referred to as BUP-XR (extended-relation of the EQ- buprenorphine), a subcuaneously injected, monthly buprenorphine treatment for OUD compared with placebo on patient-centered outcomes measuring meaningful life changes. Methods: Patient-centered outcomes were collected in a 24-week, phase 3, placebo-controlled study assessing the efficacy, safe to effect as a significantly higher for participants receiving BUP-XR 300/300 mg: difference $=3.2$, $P = 0.017$; 00010 mg: difference $=3.2$, $P = 0.002$, saffaction was significantly higher for participants receiving BUP-XR 300/ $300mg (88%, P < 0.001)$ and $300/100 mg and 10.00\%(2 \times 300 mg followed by a 100 mg) inference biology and 10.00\%participants with moderate-to-severe OUD. Measures included the$	

You can monitor your progress, skip studies (and return to them later), and leave comments!

Risk of Bias Visuals

By completing Risk of Bias, you automatically generate Risk of Bias visuals: Domain Distribution and Stoplight diagrams on Synthesis.

From: https://wiki.nested-knowledge.com/ - Nested Knowledge

Permanent link: https://wiki.nested-knowledge.com/doku.php?id=wiki:autolit:risk_of_bias&rev=1664587216

Last update: 2022/10/01 01:20